Akers BioSciences Regains Compliance with Nasdaq Listing Standards
11. Dezember 2019 09:30 ET
|
Akers Biosciences Inc.
Thorofare, New Jersey, Dec. 11, 2019 (GLOBE NEWSWIRE) -- Akers Biosciences, Inc. (the “Company”) (NASDAQ: AKER), a developer of rapid health information technologies, announced today that on...
Akers Biosciences Continues Strategic Review; Explores Leveraging its 30-years of Laboratory Operations to Enter into the Hemp and Minor Cannabinoid Processing Industry
05. Dezember 2019 08:45 ET
|
Akers Biosciences Inc.
· Establishes Advisory Board appointing Bob Hoban and Michael Patterson Thorofare, New Jersey, Dec. 05, 2019 (GLOBE NEWSWIRE) -- Akers Biosciences, Inc. (the “Company” or “we”) (NASDAQ:...
Akers Biosciences, Inc. Announces One-for-Twenty Four Reverse Stock Split
22. November 2019 09:15 ET
|
Akers Biosciences Inc.
THOROFARE, N.J., Nov. 22, 2019 (GLOBE NEWSWIRE) -- Akers Biosciences, Inc. (NASDAQ: AKER), (“Akers Bio” or the "Company"), a developer of rapid health information technologies, today announced that...
Akers Biosciences Announces Lifting of Temporary Suspension of Trading on the London Stock Exchange
26. Juli 2018 07:00 ET
|
Akers Biosciences Inc
THOROFARE, N.J., July 26, 2018 (GLOBE NEWSWIRE) -- Akers Biosciences, Inc. (NASDAQ: AKER) (AIM: AKR.L), (“Akers Bio” or the "Company"), a developer of rapid health information technologies,...